The proportion of patients with NAT1 and NAT2 genes predictive of slow acetylation phenotype was not statistically significantly different between the patients who developed TMP/SMX-related hepatotoxicity and those who did not (Table 1). Here, NAT2 is linked to hepatotoxicity.